Biotechnology, specialty pharmaceutical and medical device companies are raising capital by providing future sales revenues in exchange for upfront payments (royalties).
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biotechnology, specialty pharmaceutical and medical device companies are raising capital by providing future sales revenues in exchange for upfront payments (royalties).